...
首页> 外文期刊>Current oncology >Use of hormonal therapy in senior breast cancer patients treated with or without radiotherapy
【24h】

Use of hormonal therapy in senior breast cancer patients treated with or without radiotherapy

机译:激素疗法在接受或不接受放射治疗的老年乳腺癌患者中的应用

获取原文

摘要

Purpose Breast cancer treatment guidelines state that radiotherapy (rt) can reasonably be omitted in selected women 70 years of age and older if they take adjuvant endocrine therapy (aet) for 5 years. We aimed to assess persistence and adherence to aet in women 70 years of age and older, and to examine differences between rt receivers and non-receivers. Methods Quebec’s medical service and pharmacy claims databases were used to identify seniors undergoing breast-conserving surgery (1998–2005) and initiating aet. Cox proportional hazards models were used to identify predictors of aet non-persistence. Results Of 3180 women who initiated aet (mean age: 77.5 years), 28% did not receive rt. During the subsequent 5 years, 32% of patients who initiated aet did not persist, 2% filled only a single prescription, and 22% switched medications. Compared with rt receivers, non-receivers discontinued more often (35.5% vs. 30.1%) and earlier (1.4 years vs. 1.6 years). They also became nonadherent earlier (medication possession ratio & 80% at year 3 vs. at year 5). Predictors of nonpersistence included rt omission [hazard ratio (hr): 1.26; 95% confidence interval (ci): 1.09 to 1.46]; age (hr per decade increase: 1.15; 95% ci: 1.01 to 1.31); new medications (hr per medication: 1.01; 95% ci: 1.00 to 1.02); and hospitalizations during aet, (hr per hospitalization: 1.08; 95% ci: 1.05 to 1.11). In a subanalysis of rt non-receivers, significant predictors included hospitalizations (hr: 1.07; 95% ci: 1.02 to 1.12) and medications at aet start (hr: 0.94; 95% ci: 0.91 to 0.97). Conclusions Suboptimal use of aet was observed in at least one third of women. In rt non-receivers, aet use was worse than it was in rt receivers. Initiation of new medications and hospitalizations increased the risk of non-persistence. ? Normal 0 false false false EN-CA JA AR-SA
机译:目的乳腺癌治疗指南规定,如果选择接受辅助内分泌治疗(aet)5年,则70岁以上的某些女性可以合理地省略放射治疗(rt)。我们旨在评估70岁及以上女性对aet的坚持和坚持,并研究rt接受者和非接受者之间的差异。方法使用魁北克省的医疗服务和药房索赔数据库来识别进行保乳手术(1998-2005年)并开始aet的老年人。使用Cox比例风险模型确定aet非持续性的预测因子。结果在3180名发起aet的女性(平均年龄:77.5岁)中,有28%的女性没有接受rt。在随后的5年中,发起aet的患者中有32%未能坚持下去,只有2%的患者只接受一次处方,而22%的患者则选择了替代药物。与rt接收者相比,非接收者的停药频率更高(35.5%vs. 30.1%)和更早(1.4岁vs. 1.6岁)。他们也较早地变得不依从(第三年与第五年的药物拥有率小于80%)。持久性的预测因素包括rt遗漏[危险比(hr):1.26; 95%置信区间(ci):1.09至1.46];年龄(每十年增加的小时数:1.15; 95%ci:1.01至1.31);新药(每药小时数:1.01; 95%ci:1.00至1.02);以及在aet期间住院(每次住院时:1.08; 95%ci:1.05至1.11)。在rt未接受者的子分析中,重要的预测因素包括住院(hr:1.07; 95%ci:1.02至1.12)和开始治疗时的药物使用(hr:0.94; 95%ci:0.91至0.97)。结论在至少三分之一的女性中观察到次优的aet使用。在rt非接收者中,使用aet比在rt接收者中更糟。开始新药和住院治疗增加了不坚持的风险。 ?正常0假假假EN-CA JA AR-SA

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号